Stewart & Patten Co. LLC Has $354,000 Holdings in Danaher Co. (NYSE:DHR)

Stewart & Patten Co. LLC lifted its holdings in Danaher Co. (NYSE:DHR) by 3.3% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,419 shares of the conglomerate’s stock after acquiring an additional 45 shares during the period. Stewart & Patten Co. LLC’s holdings in Danaher were worth $354,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Alpine Global Management LLC bought a new stake in Danaher during the third quarter worth about $1,489,000. United Services Automobile Association grew its stake in Danaher by 17.2% during the third quarter. United Services Automobile Association now owns 17,632 shares of the conglomerate’s stock worth $4,374,000 after buying an additional 2,589 shares in the last quarter. First Business Financial Services Inc. grew its stake in Danaher by 8.6% during the third quarter. First Business Financial Services Inc. now owns 1,000 shares of the conglomerate’s stock worth $248,000 after buying an additional 79 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Danaher by 8.5% during the third quarter. Jones Financial Companies Lllp now owns 855 shares of the conglomerate’s stock worth $212,000 after buying an additional 67 shares in the last quarter. Finally, Braidwell LP grew its stake in Danaher by 39.4% during the third quarter. Braidwell LP now owns 77,200 shares of the conglomerate’s stock worth $19,153,000 after buying an additional 21,800 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Trading Down 2.1 %

Danaher stock traded down $5.34 during mid-day trading on Monday, hitting $244.51. 3,887,911 shares of the stock were exchanged, compared to its average volume of 2,858,576. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The firm’s fifty day simple moving average is $255.96 and its two-hundred day simple moving average is $246.75. The stock has a market capitalization of $181.11 billion, a price-to-earnings ratio of 41.44, a PEG ratio of 3.82 and a beta of 0.84.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the previous year, the business posted $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. Analysts forecast that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Investors of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is currently 18.31%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of Danaher in a research note on Monday, June 3rd. They set a “buy” rating and a $295.00 price objective on the stock. HSBC upgraded shares of Danaher from a “hold” rating to a “buy” rating and raised their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Barclays raised their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Finally, TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Danaher presently has an average rating of “Moderate Buy” and an average price target of $269.29.

Insider Activity at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total transaction of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. 10.90% of the stock is owned by company insiders.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.